ClinicalTrialsFinder

Conditions Drugs Locations Institutions Guides Search Trials Get Alerts

Conditions
Drugs
Locations
Institutions
Guides
Search Trials
Get Alerts

Conditions
Recurrent Triple-Negative Breast Cancer
Sapporo, Hokkaido

Recurrent Triple-Negative Breast Cancer Clinical Trials in Sapporo, Hokkaido

1 recruitingSapporo, Hokkaido, Japan

Filters

Status

RecruitingNot yet recruitingEnrolling by invitationActive, not recruiting

Sex

MaleFemale

Your Age

Shows trials you qualify for by age

Phase

Phase 1Phase 2Phase 3Phase 4Early Phase 1Not Applicable

Study Type

InterventionalObservational

Country

United StatesCanadaUnited KingdomAustraliaGermanyFranceSpainItaly

Other Locations

Nagoya, Aichi-ken1
Osaka, Osaka1
Koto-ku, Tokyo1
Kashiwa-shi, Chiba1
Okayama, Okayama-ken1
Hiroshima, Hiroshima1
Sakai-shi, Osaka1
Gifu, Gifu1
Shinagawa-ku, Tokyo1
Akashi-shi, Hyōgo1

Showing 1–1 of 1 trials

Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

Recurrent Triple-Negative Breast Cancer

Yukinori Ozaki44 enrolled15 locationsNCT06976944

ClinicalTrialsFinder

Helping patients and researchers find recruiting clinical trials. Updated regularly from ClinicalTrials.gov and ANZCTR.

Browse

Browse Conditions
Browse Drugs
Browse Locations
Browse Institutions
Search Trials
Get Trial Alerts

Resources

Clinical Trial Guides
FAQ
About Us
Contact
ClinicalTrials.gov
ANZCTR

Data Source

Trial data sourced from ClinicalTrials.gov and ANZCTR (Australian New Zealand Clinical Trials Registry)

Updated regularly to reflect the latest trial information

Medical Disclaimer: This site is for informational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before making decisions about participating in a clinical trial. Trial information may change; verify details directly with the trial sponsor or at the relevant registry (ClinicalTrials.gov or ANZCTR).

© 2026 ClinicalTrialsFinder. All rights reserved.

|

Privacy Policy Terms of Service

Data provided by ClinicalTrials.gov & ANZCTR